Aclaris Therapeutics, Inc. (ACRS)

1,1700 -0,0550 (-4,49%) Al cierre: 04:00PM EDT

Aclaris Therapeutics, Inc.

701 Lee Road
Suite 103
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 86

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Neal S. Walker D.O., M.D.	Co-Founder, President, Chairman & Interim CEO	73,5k	N/A	1970
Mr. Kevin Balthaser	Chief Financial Officer	581,52k	N/A	1988
Dr. Joseph Monahan Ph.D.	Chief Scientific Officer	492,43k	N/A	1957
Mr. James Loerop	Chief Business Officer	570k	N/A	1965
Mr. Matthew Rothman J.D.	General Counsel & Corporate Secretary	N/A	N/A	N/A
Dr. Jon Jacobsen Ph.D.	Senior Vice President of Chemistry	N/A	N/A	N/A
Mr. Steve Tucker	Senior Vice President of Project Leadership	N/A	N/A	N/A
Mr. Ajay Aggarwal M.B.A., M.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Aclaris Therapeutics, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.